Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL E JONES

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1083611636
CMS profile
94620
Location
CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$129.84

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $129.84 7

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $95.86 5
Daiichi Sankyo Inc. $17.52 1
Allergan, Inc. $16.46 1

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL E JONES

NPI 1083611636 · CMS profile ID 94620

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083611636?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083611636?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083611636?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1083611636?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $129.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $20.7712/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721914773 CMS
AbbVie Inc. $16.2211/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721914769 CMS
Daiichi Sankyo Inc. $17.5210/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739501053 CMS
AbbVie Inc. $23.6210/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721914765 CMS
AbbVie Inc. $14.5505/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721914761 CMS
AbbVie Inc. $20.7004/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721914757 CMS
Allergan, Inc. $16.4604/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723573803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $217.85 9
PY2020 $129.84 7
PY2021 $337.52 11
PY2022 $257.93 9
PY2023 $258.68 17
PY2024 $310.01 9
PY2025 $392.84 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,950.60 133
PY2024 Principal investigator $457,323.22 237
PY2023 Principal investigator $533,333.42 238
PY2022 Principal investigator $150,301.11 166
PY2021 Principal investigator $55,731.60 19
PY2020 Principal investigator $143,151.70 114
PY2019 Principal investigator $258,588.69 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

238 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $5,575.00 12/29/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566973
Principal investigator 1 Genentech, Inc. $1,115.00 12/22/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566989
Principal investigator 1 Genentech, Inc. $10,035.00 12/20/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566955
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114829
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114831
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114833
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114835
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114837
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114839
Principal investigator 1 Janssen Research & Development, LLC $3,957.00 12/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114841
Principal investigator 1 Janssen Research & Development, LLC $2,590.60 12/14/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153081
Principal investigator 1 ABBVIE INC. $1,214.00 12/13/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998411583
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 12/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039766113
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 12/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039766119
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 12/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039766125
Principal investigator 1 Genentech, Inc. $7,805.00 12/08/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040567021
Principal investigator 1 Genentech, Inc. $5,575.00 12/01/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040567005
Principal investigator 1 ABBVIE INC. $90.12 11/21/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998408557
Principal investigator 1 Genentech, Inc. $3,345.00 11/20/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566873
Principal investigator 1 Genentech, Inc. $14,495.00 11/16/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566939
Principal investigator 1 Genentech, Inc. $1,115.00 11/14/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566889
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 11/14/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039777793
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/14/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039777801
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/14/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039777807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 11/14/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039777819
Principal investigator 1 Genentech, Inc. $8,920.00 11/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566905
Principal investigator 1 Genentech, Inc. $8,920.00 11/09/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566923
Principal investigator 1 Janssen Research & Development, LLC $977.40 10/30/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153079
Principal investigator 1 Janssen Research & Development, LLC $825.40 10/27/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153077
Principal investigator 1 Janssen Research & Development, LLC $1,371.00 10/26/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114813
Principal investigator 1 Janssen Research & Development, LLC $2,656.00 10/26/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114815
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 10/26/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114821
Principal investigator 1 Janssen Research & Development, LLC $3,520.00 10/26/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114823
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 10/26/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114825
Principal investigator 1 Janssen Research & Development, LLC $3,957.00 10/26/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114827
Principal investigator 1 Janssen Research & Development, LLC $3,188.00 10/20/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114817
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 10/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039776631
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 10/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039776637
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 10/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039776643
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 10/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039776649
Principal investigator 1 Janssen Research & Development, LLC $177.00 10/02/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114819
Principal investigator 1 Janssen Research & Development, LLC $1,978.80 09/29/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153075
Principal investigator 1 Janssen Research & Development, LLC $1,856.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114665
Principal investigator 1 Janssen Research & Development, LLC $169.20 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114667
Principal investigator 1 Janssen Research & Development, LLC $182.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114669
Principal investigator 1 Janssen Research & Development, LLC $185.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114671
Principal investigator 1 Janssen Research & Development, LLC $325.20 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114673
Principal investigator 1 Janssen Research & Development, LLC $350.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114675
Principal investigator 1 Janssen Research & Development, LLC $375.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114677
Principal investigator 1 Janssen Research & Development, LLC $93.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114679
Principal investigator 1 Janssen Research & Development, LLC $108.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114681
Principal investigator 1 Janssen Research & Development, LLC $169.20 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114683
Principal investigator 1 Janssen Research & Development, LLC $169.20 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114685
Principal investigator 1 Janssen Research & Development, LLC $182.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114687
Principal investigator 1 Janssen Research & Development, LLC $218.80 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114689
Principal investigator 1 Janssen Research & Development, LLC $350.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114691
Principal investigator 1 Janssen Research & Development, LLC $350.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114693
Principal investigator 1 Janssen Research & Development, LLC $375.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114695
Principal investigator 1 Janssen Research & Development, LLC $93.00 09/24/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114697
Principal investigator 1 ABBVIE INC. $45.06 09/21/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998400489
Principal investigator 1 Genentech, Inc. $15,610.00 09/18/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566737
Principal investigator 1 Janssen Research & Development, LLC $8.50 09/15/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804UCO2001 No dispute reported 06/30/2026 986114811
Principal investigator 1 Genentech, Inc. $4,460.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039757917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039757929
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039757935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039800261
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039800277
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 09/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039800285
Principal investigator 1 ABBVIE INC. $1,950.00 09/08/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 998399051
Principal investigator 1 ABBVIE INC. $7,963.60 09/07/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998398971
Principal investigator 1 Genentech, Inc. $4,460.00 08/31/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566753
Principal investigator 1 Genentech, Inc. $3,345.00 08/31/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566839
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/30/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114807
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/30/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114809
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114747
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114749
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114751
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114753
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114755
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114757
Principal investigator 1 Janssen Research & Development, LLC $177.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114759
Principal investigator 1 Janssen Research & Development, LLC $2,608.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114761
Principal investigator 1 Janssen Research & Development, LLC $2,826.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114763
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114765
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114767
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114769
Principal investigator 1 Janssen Research & Development, LLC $3,217.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114771
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114773
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114775
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114777
Principal investigator 1 Janssen Research & Development, LLC $3,453.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114779
Principal investigator 1 Janssen Research & Development, LLC $3,520.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114781
Principal investigator 1 Janssen Research & Development, LLC $3,520.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114783
Principal investigator 1 Janssen Research & Development, LLC $3,520.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114785
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114787
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114789
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114791
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114793
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114795
Principal investigator 1 Janssen Research & Development, LLC $3,739.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114797
Principal investigator 1 Janssen Research & Development, LLC $4,016.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114799
Principal investigator 1 Janssen Research & Development, LLC $4,016.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114801
Principal investigator 1 Janssen Research & Development, LLC $4,016.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114803
Principal investigator 1 Janssen Research & Development, LLC $4,016.00 08/25/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114805
Principal investigator 1 Janssen Research & Development, LLC $874.20 08/24/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $108.42 08/18/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 1039748787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $542.10 08/18/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 1039748793
Principal investigator 1 Genentech, Inc. $2,230.00 08/14/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566855
Principal investigator 1 Janssen Research & Development, LLC $152.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114711
Principal investigator 1 Janssen Research & Development, LLC $239.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114713
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114715
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114717
Principal investigator 1 Janssen Research & Development, LLC $274.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114719
Principal investigator 1 Janssen Research & Development, LLC $450.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114721
Principal investigator 1 Janssen Research & Development, LLC $459.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114723
Principal investigator 1 Janssen Research & Development, LLC $541.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114725
Principal investigator 1 Janssen Research & Development, LLC $152.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114727
Principal investigator 1 Janssen Research & Development, LLC $239.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114729
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114731
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114733
Principal investigator 1 Janssen Research & Development, LLC $242.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114735
Principal investigator 1 Janssen Research & Development, LLC $272.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114737
Principal investigator 1 Janssen Research & Development, LLC $274.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114739
Principal investigator 1 Janssen Research & Development, LLC $450.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114741
Principal investigator 1 Janssen Research & Development, LLC $459.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114743
Principal investigator 1 Janssen Research & Development, LLC $541.00 08/14/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114745
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039755529
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039755535
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039755541
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039755547
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039755553
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039797089
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039797097
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039797105
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039797113
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 08/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039797121
Principal investigator 1 ABBVIE INC. $2,032.40 08/10/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998394419
Principal investigator 1 Genentech, Inc. $3,345.00 08/08/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566721
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/03/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114705
Principal investigator 1 Janssen Research & Development, LLC $1,570.00 08/03/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114707
Principal investigator 1 Janssen Research & Development, LLC $7,740.00 08/03/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
78934804CRD2001 No dispute reported 06/30/2026 986114709
Principal investigator 1 Janssen Research & Development, LLC $1,206.40 07/31/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153071
Principal investigator 1 Genentech, Inc. $1,115.00 07/27/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566823
Principal investigator 1 Genentech, Inc. $10,035.00 07/24/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566791
Principal investigator 1 Janssen Research & Development, LLC $2,009.00 07/19/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114703
Principal investigator 1 Genentech, Inc. $23,415.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764449
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764455
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764467
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764473
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764479
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764487
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039764499
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809667
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809679
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809703
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809729
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809741
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 07/17/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039809767
Principal investigator 1 ABBVIE INC. $40.25 07/13/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998391363
Principal investigator 1 ABBVIE INC. $80.50 07/13/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998391365
Principal investigator 1 ABBVIE INC. $90.12 07/13/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998391457
Principal investigator 1 ABBVIE INC. $1,214.00 07/13/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998391459
Principal investigator 1 Janssen Research & Development, LLC $1,524.00 07/03/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114699
Principal investigator 1 Janssen Research & Development, LLC $2,456.00 07/03/2023 Non-covered Recipient Entity
Tri State Gastroenterology Associates
CNTO1959CRD3004 No dispute reported 06/30/2026 986114701
Principal investigator 1 Celgene Corporation $7,000.00 06/21/2023 Non-covered Recipient Entity
Tristate Gastroenterology Associates
Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagiti No dispute reported 06/30/2026 1026487545
Principal investigator 1 Genentech, Inc. $51,290.00 06/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566659
Principal investigator 1 Genentech, Inc. $3,345.00 06/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566675
Principal investigator 1 Genentech, Inc. $3,500.00 06/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566691
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 06/12/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039721395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 06/12/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039721401
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 06/12/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039721413
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 06/12/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039721419
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 06/12/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039721425
Principal investigator 1 Janssen Research & Development, LLC $1,560.40 06/01/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153069
Principal investigator 1 Genentech, Inc. $51,290.00 05/29/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566643
Principal investigator 1 Genentech, Inc. $3,500.00 05/25/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040566705
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 05/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039713407
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 05/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039713427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 05/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039713439
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 05/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039713449
Principal investigator 1 ABBVIE INC. $1,214.00 05/11/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998383173
Principal investigator 1 Janssen Research & Development, LLC $960.20 05/01/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153067
Principal investigator 1 Janssen Research & Development, LLC $1,839.00 04/26/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115005
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $948.00 04/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039715427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 04/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039715545
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 04/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039715663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 04/13/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039715805
Principal investigator 1 ABBVIE INC. $8,723.20 04/12/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998377623
Principal investigator 1 Janssen Research & Development, LLC $5,871.00 04/03/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986114999
Principal investigator 1 Janssen Research & Development, LLC $1,839.00 04/03/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115001
Principal investigator 1 Janssen Research & Development, LLC $1,082.40 03/27/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153059
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 03/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039831741
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 03/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039831767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 03/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039831787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 03/15/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039831809
Principal investigator 1 Janssen Research & Development, LLC $3,206.65 03/10/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $35.30 03/10/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 1039707773
Principal investigator 1 Janssen Research & Development, LLC $169.20 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115013
Principal investigator 1 Janssen Research & Development, LLC $182.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115015
Principal investigator 1 Janssen Research & Development, LLC $2,613.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115017
Principal investigator 1 Janssen Research & Development, LLC $325.20 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115019
Principal investigator 1 Janssen Research & Development, LLC $350.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115021
Principal investigator 1 Janssen Research & Development, LLC $375.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115023
Principal investigator 1 Janssen Research & Development, LLC $5,871.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115025
Principal investigator 1 Janssen Research & Development, LLC $93.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115027
Principal investigator 1 Janssen Research & Development, LLC $182.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115029
Principal investigator 1 Janssen Research & Development, LLC $350.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115031
Principal investigator 1 Janssen Research & Development, LLC $375.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115033
Principal investigator 1 Janssen Research & Development, LLC $5,871.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115035
Principal investigator 1 Janssen Research & Development, LLC $93.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115037
Principal investigator 1 Janssen Research & Development, LLC $2,720.00 02/24/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115039
Principal investigator 1 Janssen Research & Development, LLC $989.60 02/24/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153063
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814435
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814443
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 02/10/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039814477
Principal investigator 1 ABBVIE INC. $2,326.00 02/09/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998369089
Principal investigator 1 Celgene Corporation $6,708.00 02/08/2023 Non-covered Recipient Entity
Tristate Gastroenterology Associates
Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc No dispute reported 06/30/2026 1026487561
Principal investigator 1 Janssen Research & Development, LLC $2,087.00 02/02/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115011
Principal investigator 1 Janssen Research & Development, LLC $1,613.00 01/30/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 986153065
Principal investigator 1 Janssen Research & Development, LLC $1,898.80 01/12/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115007
Principal investigator 1 Janssen Research & Development, LLC $2,210.80 01/12/2023 Non-covered Recipient Entity
Tri State Dgstv Disorder Ctr
CNTO1959CRD3004 No dispute reported 06/30/2026 986115009
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854831
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854847
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854879
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $461.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854895
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854911
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $148.00 01/11/2023 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES PSC
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 1039854927
Principal investigator 1 ABBVIE INC. $1,433.20 01/05/2023 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 998364217